Bronchiolitis obliterans after allo-SCT: Clinical criteria and treatment options

Bone Marrow Transplantation

Volumn 47, Issue 8, 2012, Pages 1020-1029

  Uhlving, H H ^a   Buchvald, F ^a   Heilmann, C J ^a   Nielsen, K G ^a   Gormsen, M ^a   Muller K G ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

allogeneic haematopoietic SCT; bronchiolitis obliterans; chronic graft versus host disease; methylprednisolone; treatment outcome

Indexed keywords

AZITHROMYCIN; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; ETANERCEPT; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; MONTELUKAST; PENTOSTATIN; PLACEBO; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; EXTRACORPOREAL PHOTOPHERESIS; GRAFT VERSUS HOST REACTION; HOT FLUSH; HUMAN; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINUS BRADYCARDIA;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BRONCHIOLITIS OBLITERANS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHYLPREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROIDS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864882318     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.161     Document Type: Review

References (98)

1. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16(Suppl 1): S106-S114.
2. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666. (Pubitemid 38351785)
3. Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol 2011; 93: 375-382.
4. Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2009; 44: 303-308.
5. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graftversus-leukemia effect. Blood 2003; 102: 4236-4242. (Pubitemid 37487013)
6. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988; 72: 621-627.
7. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-376. (Pubitemid 19231290)
8. Schultz KR, Green GJ, Wensley D, Sargent MA, Magee JF, Spinelli JJ et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994; 84: 3212-3220. (Pubitemid 24328117)
9. Santo Tomas LH, Loberiza Jr FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161. (Pubitemid 40994467)
10. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-214. (Pubitemid 36920975)
11. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306-314.
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
13. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233. (Pubitemid 40045609)
14. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276. (Pubitemid 11174888)
15. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
16. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226. (Pubitemid 32183742)
17. Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J, Cordier JF. Post-transplant obstructive lung disease ('bronchiolitis obliterans'): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8: 551-558.
18. Schulman LL, Weinberg AD, McGregor CC, Suciu-Foca NM, Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001; 163: 437-442. (Pubitemid 32158525)
19. Schwarer AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation 1992; 54: 1002-1008. (Pubitemid 23005536)
20. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-656. (Pubitemid 18041859)
21. Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100: 680-687. (Pubitemid 28126099)
22. Duncan CN, Buonanno MR, Barry EV, Myers K, Peritz D, Lehmann L. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 971-975. (Pubitemid 351850502)
23. Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica 2007; 92: 558-561. (Pubitemid 350144303)
24. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201. (Pubitemid 29153620)
25. Bruno B, Souillet G, Bertrand Y, Werck-Gallois MC, So SA, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004; 34: 143-147. (Pubitemid 39077105)
26. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004; 33: 509-517. (Pubitemid 38425782)
27. Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005; 35: 1195-1200. (Pubitemid 40895176)
28. Yousem SA. The histological spectrum of pulmonary graftversus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-675.
29. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al. Histopathologic diagnosis of chronic graftversus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12: 31-47. (Pubitemid 43034096)
30. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310. (Pubitemid 34224094)
31. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498-3506. (Pubitemid 350097005)
32. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46. (Pubitemid 46365005)
33. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
34. Meloni F, Vitulo P, Bianco AM, Paschetto E, Morosini M, Cascina A et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004; 77: 762-766. (Pubitemid 38366987)
35. Nakagiri T, Inoue M, Morii E, Minami M, Sawabata N, Utsumi T et al. Local IL-17 production and a decrease in peripheral blood regulatory T cells in an animal model of bronchiolitis obliterans. Transplantation 2010; 89: 1312-1319.
36. Laan M, Linden. IL-17 as a potential target for modulating airway neutrophilia. Curr Pharm Des 2002; 8: 1855-1861.
37. Vanaudenaerde BM, Wuyts WA, Dupont LJ, Van Raemdonck DE, Demedts MM, Verleden GM. Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 1280-1283. (Pubitemid 37324703)
38. Zheng L, Whitford HM, Orsida B, Levvey BJ, Bailey M, Walters EH et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant 2006; 6: 599-608. (Pubitemid 43382149)
39. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570. (Pubitemid 44330550)
40. Verleden GM, Vos R, De Vleeschauwer SI, Willems-Widyastuti A, Verleden SE, Dupont LJ et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009; 22: 771-779.
41. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010; 51: 376-389.
42. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865-3874.
43. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007; 13: 6107-6114. (Pubitemid 350075069)
44. Kuzmina Z, Weigl R, Krenn K, Petkov V, Koermoeczi U, Rottal A et al. Excess of BAFF and distortion of B-cell homeostasis in patients with newly diagnosed bronchiolitis obliterans syndrome associated with chronic graft-versus-host disease. Bone Marrow Transplantation 2011; 46(Suppl 1): S7. Ref Type: Abstract.
45. Jaramillo A, Smith MA, Phelan D, Sundaresan S, Trulock E, Lynch J et al. Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation. Transplant Proc 1999; 31: 185-186. (Pubitemid 29127419)
46. Maruyama T, Jaramillo A, Narayanan K, Higuchi T, Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant 2005; 5: 2126-2134. (Pubitemid 41648459)
47. Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ et al. An official American thoracic society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011; 183: 1262-1279.
48. Zhu KE, Hu JY, Zhang T, Chen J, Zhong J, Lu YH. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008; 81: 461-466.
49. Gower WA, Collaco JM, Mogayzel Jr PJ. Lung function and late pulmonary complications among survivors of hematopoietic stem cell transplantation during childhood. Paediatr Respir Rev 2010; 11: 115-122.
50. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777-2785. (Pubitemid 37248846)
51. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46: 1283-1295.
52. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-1628.
53. Wolff D, Schleuning M, von HS, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1-17.
54. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005; 36: 135-138. (Pubitemid 41030629)
55. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 547-553. (Pubitemid 46629590)
56. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007; 83: 577-581. (Pubitemid 46440246)
57. Khalid M, Al SA, Saleemi S, Al DS, Zeitouni M, Al MA et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25: 490-493. (Pubitemid 40340107)
58. Lam DCL, Lam B, Wong MKY, Lu C, Au WY, Tse EWC et al. Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT-a randomized doubleblinded placebo-controlled study. Bone Marrow Transplant 2011; 46: 1551-1556.
59. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versushost disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45-52. (Pubitemid 46033391)
60. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665-667. (Pubitemid 34193637)
61. Flowers ME, Apperley JF, van BK, Elmaagacli A, Grigg A, Reddy V et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667-2674.
62. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
63. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127. (Pubitemid 36819346)
64. Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagni MR, D'Ascenzo G et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130: 271-275. (Pubitemid 41602528)
65. Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011; 46: 426-429.
66. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007; 40: 273-277. (Pubitemid 47108472)
67. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010; 95: 1935-1942.
68. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versushost disease. J Clin Oncol 2007; 25: 4255-4261. (Pubitemid 47548565)
69. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versushost disease with fibrotic features. Blood 2009; 114: 709-718.
70. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009; 114: 3718-3719.
71. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versushost disease. Bone Marrow Transplant 2003; 32: 165-170. (Pubitemid 36903440)
72. Couriel D, Carpenter PA, Cutler C, Bolañ os-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375-396. (Pubitemid 43380955)
73. De Jong PA, Dodd JD, Coxson HO, Storness-Bliss C, Paré PD, Mayo JR et al. Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning. Thorax 2006; 61: 799-804. (Pubitemid 44369406)
74. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1992; 146(5 Part 1): 1368-1369.
75. Clement A. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 2004; 24: 686-697. (Pubitemid 39406144)
76. Desmarquest P, Tamalet A, Fauroux B, Boule M, Boccon-Gibod L, Tournier G et al. Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses. Pediatr Pulmonol 1998; 26: 332-338. (Pubitemid 29006565)
77. Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL et al. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. Pediatr Pulmonol (e-pub ahead of print 26 May 2011).
78. Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007; 119: e778-e782. (Pubitemid 46407587)
79. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-vhost disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-554.
80. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100: 48-51. (Pubitemid 35177427)
81. Bergeron A, Chagnon K, Feuillet S, Chevret S, Tazi A. Prospective evaluation of the efficacy of the combination of budesonide/formoterol in obstructive airway disease after allogeneic hematopoietic stem cell transplantation]. Rev Mal Respir 2009; 26: 794-800.
82. Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics 2005; 116: 767-770. (Pubitemid 44336698)
83. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
84. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De WW, Verbeken EK et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832-843.
85. Norman BC, Jacobsohn DA, Williams KM, Au BKC, Au MA, Lee SJ et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011; 46: 1369-1373.
86. Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel C et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47: 2276-2289. (Pubitemid 350151207)
87. Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci 2004; 30: 185-187. (Pubitemid 38698331)
88. Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096-1101. (Pubitemid 41323509)
89. Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187-1193. (Pubitemid 40895175)
90. Berger M, Pessolano R, Albiani R, Asaftei S, Barat V, Carraro F et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 2007; 29: 678-687.
91. Bisaccia E, Palangio M, Gonzalez J, Adler KR, Scarborough R, Goldberg SL et al. Treatment of extensive chronic graftversus-host disease with extracorporeal photochemotherapy. J Clin Apher 2006; 21: 181-187. (Pubitemid 46579293)
92. O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115: 1459-1462. (Pubitemid 29230666)
93. Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86: 1625-1627.
94. Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424-431.
95. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009; 15: 1005-1013.
96. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M et al. Rituximab for the treatment of corticosteroidrefractory chronic graft-versus-host disease. Int J Hematol 2009; 90: 253-260.
97. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versushost disease. Blood 2006; 108: 756-762. (Pubitemid 44061381)
98. von BM, Oelschlagel U, Radke J, Stewart M, Ehninger G, Bornhauser M et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008; 86: 875-879.